PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen
Abstract
Authors
P.R. Maran A. Aiello M.R. Magrì C. Alberti E. Visentin F. Venturini G. Scroccaro